written on 12.06.2014
Tags:
,

FDA panel advises against more clinical trials for opioid constipation drugs

TAGS: ,

An FDA panel today advised the agency against requiring more large clinical studies for the cardiovascular risks of drugs that treat opioid-induced constipution, relieving drugmakers like AstraZeneca, Salix Pharmaceuticals and others from bearing the burden of further clinical safety trials.

Latest Report